Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03682224 · ClinicalTrials.gov registry record · Phase 3
Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients
A Phase 3 study, sponsored by Southern Illinois University.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
NCT03682224: Completed Phase 3 study, sponsored by Southern Illinois University.
NCT03682224 is a Phase 3 study that has completed, run by Southern Illinois University. The registered enrollment target is 57 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03682224, a Phase 3 study, has completed, sponsored by Southern Illinois University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to assess pain management after elective thoracoscopic lobectomy. The study will compare two local anesthetics that are given intra-operatively during lobectomy to see which one helps in better pain control and to see which one helps decrease the need for opioid medications. Participants will receive either Marcaine (Bupivacaine-epinephrine 0.25%, 1:200,000) or Exparel (Bupivacaine liposomal (1.3%)) and the drug will be chosen in a random fashion. Participants will be followed during the hospital stay and for one year thereafter. An visual Scale will be administered to measure pain, and opioid drug use will be measured by calculating morphine equivalent dose on each day post surgery until discharge and thereafter on 30 day, 6 month and 12 month follow-up visits. Participants will be monitored for any drug related toxicity and other co-morbid conditions for a period on one year post surgery. Overall cost for the surgery and during in hospital stay post surgery will be collected and compared between the two treatment arms.
Primary Outcome
Measured as overall intake of any drugs in the opioid class (Morphine Equivalent Dosing)
Interventions
- DRUG Liposomal Bupivacaine
- DRUG Bupivacaine-Epinephrine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2022-09-03 |
| Phase | Phase 3 |
What the finished NCT03682224 record still lists
NCT03682224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.
NCT03682224 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03682224 about?
NCT03682224 is a clinical study titled "Exparel and Marcaine for Pain Management in Thoracoscopic Lobectomy Patients". The purpose of this study is to assess pain management after elective thoracoscopic lobectomy. The study will compare two local anesthetics that are given intra-operatively during lobectomy to see which one helps in better pain control and to see which one helps decrease the need for opioid medicati...
What is the current status of trial NCT03682224?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2018-07-05. Estimated completion is 2022-09-03.
What interventions are being tested in trial NCT03682224?
The interventions under investigation include: Liposomal Bupivacaine (DRUG), Bupivacaine-Epinephrine (DRUG).
Who is sponsoring clinical trial NCT03682224?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03682224's enrollment target sits among peer trials
57 1827th of 2000 higher than 174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI